Equities analysts forecast that AxoGen, Inc. (NASDAQ:AXGN) will announce ($0.09) earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for AxoGen’s earnings, with estimates ranging from ($0.11) to ($0.06). AxoGen posted earnings of ($0.10) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 10%. The business is scheduled to announce its next earnings results on Wednesday, February 28th.

On average, analysts expect that AxoGen will report full year earnings of ($0.31) per share for the current year, with EPS estimates ranging from ($0.33) to ($0.30). For the next fiscal year, analysts anticipate that the company will report earnings of ($0.26) per share, with EPS estimates ranging from ($0.32) to ($0.20). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of analysts that follow AxoGen.

AxoGen (NASDAQ:AXGN) last posted its earnings results on Wednesday, November 1st. The medical equipment provider reported ($0.06) EPS for the quarter, meeting the consensus estimate of ($0.06). AxoGen had a negative return on equity of 91.00% and a negative net margin of 24.74%. The firm had revenue of $16.05 million for the quarter, compared to analysts’ expectations of $15.55 million. AxoGen’s quarterly revenue was up 43.2% on a year-over-year basis.

AXGN has been the subject of a number of research reports. Jefferies Group initiated coverage on AxoGen in a research note on Thursday, November 30th. They set a “buy” rating and a $35.00 price target for the company. Leerink Swann reaffirmed an “outperform” rating and set a $23.00 price target (up from $22.00) on shares of AxoGen in a research note on Saturday, September 30th. Wedbush reissued a “buy” rating and set a $27.00 price objective (up from $22.00) on shares of AxoGen in a research note on Tuesday, November 21st. Roth Capital reissued a “buy” rating and set a $21.00 price objective (up from $18.00) on shares of AxoGen in a research note on Tuesday, September 12th. Finally, Lake Street Capital raised their price objective on AxoGen from $22.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, November 21st. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. The stock has an average rating of “Buy” and a consensus target price of $26.17.

In other AxoGen news, Director Guido J. Neels sold 1,150,000 shares of the firm’s stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $19.74, for a total transaction of $22,701,000.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Jamie Mark Grooms sold 21,290 shares of the firm’s stock in a transaction dated Wednesday, December 6th. The shares were sold at an average price of $26.22, for a total value of $558,223.80. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,293,990 shares of company stock valued at $26,494,898. 9.33% of the stock is owned by corporate insiders.

Hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE boosted its holdings in AxoGen by 8.7% during the first quarter. Bank of America Corp DE now owns 10,183 shares of the medical equipment provider’s stock valued at $106,000 after purchasing an additional 814 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of AxoGen by 33.9% in the second quarter. Schwab Charles Investment Management Inc. now owns 51,300 shares of the medical equipment provider’s stock valued at $860,000 after acquiring an additional 13,000 shares during the last quarter. Rhumbline Advisers raised its stake in shares of AxoGen by 11.4% in the second quarter. Rhumbline Advisers now owns 28,720 shares of the medical equipment provider’s stock valued at $481,000 after acquiring an additional 2,945 shares during the last quarter. Bank of New York Mellon Corp raised its stake in shares of AxoGen by 80.7% in the second quarter. Bank of New York Mellon Corp now owns 160,354 shares of the medical equipment provider’s stock valued at $2,685,000 after acquiring an additional 71,609 shares during the last quarter. Finally, Neuberger Berman Group LLC bought a new position in shares of AxoGen in the second quarter valued at approximately $201,000. 66.00% of the stock is currently owned by institutional investors and hedge funds.

AxoGen (AXGN) traded up $0.20 on Thursday, reaching $28.15. The company had a trading volume of 277,300 shares, compared to its average volume of 346,800. AxoGen has a 12-month low of $8.75 and a 12-month high of $28.90. The company has a current ratio of 3.55, a quick ratio of 2.95 and a debt-to-equity ratio of 1.93. The firm has a market cap of $952.92, a PE ratio of -70.38 and a beta of 0.40.

ILLEGAL ACTIVITY WARNING: “AxoGen, Inc. (AXGN) Expected to Post Earnings of -$0.09 Per Share” was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another website, it was illegally stolen and reposted in violation of US and international trademark & copyright legislation. The original version of this piece of content can be read at https://www.americanbankingnews.com/2018/01/04/axogen-inc-axgn-expected-to-post-earnings-of-0-09-per-share.html.

AxoGen Company Profile

AxoGen, Inc provides surgical solutions for peripheral nerve injuries. The company’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments.

Get a free copy of the Zacks research report on AxoGen (AXGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen and related companies with MarketBeat.com's FREE daily email newsletter.